

CMOs and CDMOs are riding the wave to success

Contract manufacturing organizations and contract development manufacturing organizations in pharma and medical devices continue to make waves from the ripple effect of the response to COVID and gaps in the supply chain.

Increased competition and decreased profit margins

are forcing large pharma companies to shift their focus to core competencies and outsource drug manufacturing and development.

Global CDMO market momentum

\$217.6 BILLION
2021

\$439 BILLION
2030

CAGR 9.2%
2019-2026

Making waves in the CMO pharma market



Expiring patents

Increasing investments in pharmaceutical R&D



Commitment to advancing manufacturing technologies by CMOs

Growing demand for generic drugs



Predicted to make the most waves by 2028

NORTH AMERICA
36.4%

EUROPE
21.9%

BRIC NATIONS
14.8%



As a CMO/CDMO you are positioned to solve manufacturing and drug development challenges pharma companies are facing.

Are you prepared to solve your own challenges from using manual transactional processes without predictive data and analytics capability?



More than 800 active Investigational New Drugs (IND) are waiting FDA approval.

Wipe out your challenges with accuracy and transparency using a single source of truth for:



Contract variables



Intellectual property rights and royalties



Cost and margins



Data and analytics

Ready to make some waves

CMOs/CDMOs are quickly becoming essential in the pharma and medical device industries and are likely here to stay.

Learn more about how you can prepare to grow and create the optimal conditions for your success.

[READ THE BLOG](#)

Sources: Grand View Research, Visiongain, Research and Markets

© Copyright 2022 Vistex, Inc. All rights reserved.
info@vistex.com | www.vistex.com

Vistex

Now it all adds up